Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlanbia Regulatory News (GLB)

Share Price Information for Glanbia (GLB)

Share Price is delayed by 15 minutes
Get Live Data
24.20    0.00 (0.00%)
Bid:
22.80
Ask:
24.00
Spread: 1.20 (5.263%)
Market Cap: €5.85b
GLB Live PriceLast checked at - London Stock Exchange

Intraday Glanbia Share Chart

Glanbia CMD and New Medium-Term Targets

19 Nov 2025 07:00

RNS Number : 0740I
Glanbia PLC
19 November 2025
Β 

Glanbia plc Capital Markets Day and New Medium-Term Targets

19 November 2025, Glanbia plc ("Glanbia" or the "Group") is holding a Capital Markets Day ("CMD") today. The event will focus on Glanbia's growth strategy and associated financial targets from 2026 to 2028.

Hugh McGuire, CEO of Glanbia said: "Glanbia sits at the centre of powerful consumer megatrends, focused on fast-growing health and wellness categories. Through our portfolio of leading brands and ingredients, we help consumers around the world to achieve their health, fitness and nutrition goals. Today's event will showcase how we are sharpening our focus to achieve our three year growth ambition and capitalise on the significant opportunities ahead. We are well positioned to deliver on our ambition to drive growth and shareholder returns."

Medium-term financial targets

The financial metrics for the 2026 to 2028 financial years which will be outlined at the CMD are as follows:

Group annual targets:

Β· Adjusted earnings per share ("EPS") growth of 7% to 11% (on a constant currency basis);

Β· Operating cash conversion of EBITDA 85%+;

Β· Return on capital employed ("ROCE") of 10% to 13%; and

Β· Progressive dividend maintained with target payout ratio range of 30% to 40%.

By Segment:

Β· Performance Nutrition:

oΒ  Annual organic revenue growth* of 5% to 7%; and

oΒ  Total three-year EBITDA margin progression of 250 basis points from FY 2025 reported base**

Β· Health and Nutrition:

oΒ  Annual organic revenue growth of 4% to 6%; and

oΒ  EBITDA margin range of 17% to 19%.

Β· Dairy Nutrition:

oΒ  Annual EBITDA range of approximately $150 million to $160 million.

Β 

Event Details and Webcast

The CMD will be held at the London Stock Exchange and will run from 2.00pm GMT to approximately 4.30pm GMT. The event will be broadcast live via a webcast. Details on how to register and view the webcast can be found at the following link: https://edge.media-server.com/mmc/p/imc9dzgu/

Following the event, todays webcast (including presentations) will be available for playback on www.glanbia.com

*FY 2025 base excludes revenue from brands disposed during 2025

**Target PN EBITDA margin progression is total for the three years 2026 to 2028.

ENDS

Β 

Cautionary statement

This announcement contains forward-looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this announcement. Due to the inherent uncertainties, including both economic and business risk factors underlying such forward looking information, actual results may differ materially from those expressed or implied by these forward-looking statements. The Directors do not undertake any obligation to update any forward-looking statements contained in this announcement, whether as a result of new information, future events, or otherwise, except as required by law.

Β 

For further information contact

Glanbia plc +353 56 777 2200Β 

Β 

Mark Garvey, Group Finance Director

Β 

Liam Hennigan, Group Secretary & Head of Investor Relations: +353 (0) 86 046 8375

Β 

Lauren O'Sullivan, Investor Relations Manager: +353 (0)85 741 7861

Β 

Martha Kavanagh, Director of Corporate Affairs: +353 (0)87 646 2006

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCBPBMTMTTBTBA
Date   Source Headline
29th Jun 20267:00 amRNSTransaction in Own Shares
25th Jun 20267:00 amRNSTransaction in Own Shares
24th Jun 20267:00 amRNSTransaction in Own Shares
23rd Jun 20267:00 amRNSTransaction in Own Shares
22nd Jun 20267:00 amRNSTransaction in Own Shares
19th Jun 20267:00 amRNSTransaction in Own Shares
18th Jun 20264:59 pmRNSDirectorate change
18th Jun 20267:00 amRNSTransaction in Own Shares
17th Jun 20262:00 pmRNSDirector/PDMR Shareholding
17th Jun 20267:00 amRNSTransaction in Own Shares
16th Jun 202612:30 pmRNSHolding(s) in Company
16th Jun 20267:00 amRNSTransaction in Own Shares
15th Jun 20267:00 amRNSTransaction in Own Shares
12th Jun 20267:05 amRNSResult -Tirlán Equity Placement&Off MarketPurchase
12th Jun 20267:00 amRNSRESULT OF SECONDARY SHARE SALE
12th Jun 20267:00 amRNSTransaction in Own Shares
11th Jun 20265:06 pmRNSTirlán Equity Placement and Off Market Purchase
11th Jun 20265:06 pmRNSPROPOSED SECONDARY PLACING & DIRECTED BUYBACK
11th Jun 20267:00 amRNSTransaction in Own Shares
10th Jun 20267:00 amRNSTransaction in Own Shares
9th Jun 20267:00 amRNSTransaction in Own Shares
8th Jun 20267:00 amRNSTransaction in Own Shares
5th Jun 20267:00 amRNSTransaction in Own Shares
4th Jun 20267:00 amRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSTransaction in Own Shares
2nd Jun 20264:24 pmRNSTotal Voting Rights
2nd Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20267:00 amRNSTransaction in Own Shares
28th May 20267:00 amRNSTransaction in Own Shares
27th May 20267:00 amRNSTransaction in Own Shares
26th May 20267:00 amRNSTransaction in Own Shares
22nd May 20266:28 pmRNSTransaction in Own Shares
22nd May 20267:00 amRNSTransaction in Own Shares
21st May 20262:36 pmRNSDirector/PDMR Shareholding
21st May 20267:00 amRNSTransaction in Own Shares
20th May 20267:00 amRNSTransaction in Own Shares
19th May 20267:00 amRNSTransaction in Own Shares
18th May 20267:00 amRNSTransaction in Own Shares
15th May 20267:00 amRNSTransaction in Own Shares
14th May 20267:00 amRNSTransaction in Own Shares
13th May 20267:00 amRNSTransaction in Own Shares
12th May 20267:00 amRNSTransaction in Own Shares
11th May 20267:00 amRNSTransaction in Own Shares
8th May 20267:00 amRNSTransaction in Own Shares
7th May 20267:00 amRNSTransaction in Own Shares
1st May 20263:38 pmRNSResult of AGM
30th Apr 20264:27 pmRNSTotal Voting Rights
29th Apr 20267:00 amRNSFirst Quarter 2026 Interim Management Statement
29th Apr 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.